No Data
No Data
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
Express News | Cidara Therapeutics Strengthens Its Scientific Advisory Board With Infectious Disease Experts
H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24